In fulminant hepatic failure (FHF), the therapeutic effects of MSCs are achieved primarily by reducing hepatic CD4+ T-cell infiltration and activation, inhibiting T helper 1 (Th1) cells, and inducing Treg cells. Here, CD4 is linked to TNF receptor 1-associated periodic fever syndrome.